Thompson Street Capital Partners Portfolio Company BioIVT Acquires Biological Specialty Corporation
ST. LOUIS (November 5, 2018) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioIVT, a leading global provider of research models and value-added research services for drug discovery and development, has acquired Colmar, Pennsylvania-based Biological Specialty Corporation (BSC), a supplier of human blood products and components to the life sciences research community. Terms of the transaction were not disclosed.
BSC (www.biospecialty.com) has served the life sciences research community for more than 37 years. Its acquisition will boost BioIVT’s supply of leukopaks, plasma and sera, and enhance its ability to support the in vitro diagnostic market. Products provided by BSC include blood, plasmas and sera, as well as white blood cells, and various other human biologicals, all collected at its own FDA-registered donor centers.
In addition to its Colmar headquarters, BSC has two additional FDA-registered donor centers in Allentown and Reading, Pennsylvania. BioIVT plans to retain BSC’s three locations and all of its employees.